Sold as Cortrosyn, Cosyntropin. Every FDA application for this active ingredient: 2 branded and 2 generic.
As of Nov 15, 2026, FDA lists 4 applications for Cosyntropin (sold as Cortrosyn, Cosyntropin), first approved Apr 22, 1970, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Cortrosyn | Part B | $87K | +15% | 2,752 |
| Prevalence of Adrenal Insufficiency and Associated Factors in Rheumatoid Arthritis Patients Using Low-dose Corticosteroids.Reumatoid Arthritis, Corticosteroids Adverse Reaction · Bursa Yuksek Ihtisas Training and Research Hospital | — | Recruiting | Oct 8, 2026 |
| Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney DiseaseType 2 Diabetes, Chronic Kidney Diseases · Brigham and Women's Hospital | Early phase 1 | Active, not recruiting | Jan 5, 2024 |
| Updated Diagnostic Cortisol Values for Adrenal InsufficiencyAdrenal Insufficiency · Montefiore Medical Center | Not applicable | Recruiting | Dec 8, 2021 |
| Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)Radiotracer, Hypertension · Benjamin Viglianti | Early phase 1 | Recruiting | Sep 11, 2020 |
| Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal WomenSleep Restriction · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Early phase 1 | Active, not recruiting | Jul 30, 2019 |
| Screening and Stimulation Testing for Residual Secretion of Adrenal Steroid Hormones in Autoimmune Addison's DiseasePrimary Adrenal Insufficiency · University of Bergen | Not applicable | Active, not recruiting | Jan 4, 2019 |
| NeSST2: The Development of a Noninvasive Short Synacthen TestAdrenal Suppression · Sheffield Children's NHS Foundation Trust | Phase 2 | Recruiting | May 2, 2018 |
| Hormonal Mechanisms of Sleep Restriction - Axis StudySleep Restriction · Peter y. Liu | Phase 1 | Active, not recruiting | May 8, 2017 |
| Apr 22, 1970 | CortrosynNDA 16750 · New molecular entity | Amphastar Pharms Inc | 19 | Marketed |
| Feb 21, 2008 | CosyntropinNDA 22028 · New formulation or manufacturer | Sandoz | 4 | Discontinued |
| Dec 17, 2009 | CosyntropinANDA 90574 | Pharmobedient | 0 | Discontinued |
| Jun 29, 2012 | CosyntropinANDA 202147 | Sandoz | 2 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA